Orion Oyj Class A (ORNAV) Stock Price & News

ORNAV:HEL

Orion Oyj Class A

€86.00

0.00%

(0.00) 1D

Oct 14, 6:29:55 PM GMT+3 · EUR

All symbols

	Symbol	Price	Change	% Change

Generating top insights for ORNAV...

Mkt. cap

12.15B

Avg. vol.

5.13K

Volume

0.00

Dividend

2.09%

Quarterly dividend

€0.45

Ex-dividend date

Oct 15, 2025

P/E ratio

20.60

52-wk high

€84.40

52-wk low

€56.30

EPS

€4.17

Shares outstanding

31.15M

No. of employees

Mkt. cap

12.15B

Avg. vol.

5.13K

Volume

0.00

Dividend

2.09%

Quarterly dividend

€0.45

Ex-dividend date

Oct 15, 2025

P/E ratio

20.60

52-wk high

€84.40

52-wk low

€56.30

EPS

€4.17

Shares outstanding

31.15M

No. of employees

Related stocks

News stories

From web sources and news partners

Benzinga

26 minutes ago

Stock Market: Will S&P 500 Open Up or Down Today?

Foreign Policy Journal

1 hour ago

U.S. Markets Close Lower As Tech Selloff Drags Down Dow Jones Industrial Average (DJIA), S&P 500

TradingView

3 hours ago

Dow, S&P 500, Nasdaq Decline Amid Hot Inflation Data, AI Selloff: CRWV, NBIS, NVDA, IBRX Stocks In Focus

The Motley Fool

4 hours ago

The S&P 500 Has Risen 30.6% in the First 20 Months of Trump's Second Term, Just Ahead of the 28.5% Gain Over the Same Stretch of His First Term. Here's Why That Comparison Matters for Investors Heading Into the Midterms.

Profile

Orion Corporation, founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland. Orion's class A and B shares are listed on the Helsinki Stock Exchange. Wikipedia

About Orion Oyj Class A

CEOLiisa Hurme

Employees4K

Founded1917

Headquarters-

SectorPharmaceutical industry

Websiteorionpharma.com

All values in EUR	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	423.20M	695.30M	417.70M	521.60M
Cost of goods sold	169.00M	186.60M	163.70M	181.70M
Cost of revenue	169.00M	186.60M	163.70M	181.70M
Research and development expenses	49.80M	70.60M	48.30M	62.20M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	84.60M	110.30M	91.90M	98.90M
Operating expense	133.20M	180.40M	139.30M	163.40M
Total operating expenses	302.20M	367.00M	303.00M	345.10M
Operating income	121.00M	328.30M	114.70M	176.50M
Other non operating income	-	-500.00K	100.00K	-
EBT including unusual items	120.40M	327.10M	113.40M	175.80M
EBT excluding unusual items	120.40M	327.30M	113.40M	175.80M
Income tax expense	24.40M	66.60M	23.00M	35.60M
Effective tax rate	20.27%	20.36%	20.28%	20.25%
Other operating expenses	-1.20M	-500.00K	-900.00K	2.30M
Net income	96.00M	260.50M	90.40M	140.20M
Net profit margin	22.68%	37.47%	21.64%	26.88%
Earnings per share	0.68	1.85	0.64	1.00
Interest and investment income	-	4.60M	-	-
Interest expense	-600.00K	-5.40M	-1.40M	-700.00K
Net interest expenses	-600.00K	-800.00K	-1.40M	-700.00K
Depreciation and amortization charges	-	-	-	-
EBITDA	135.10M	336.50M	130.40M	191.80M
Gain or loss from assets sale	-	100.00K	-	-

Finance

Ask anything